StockNews.AI
OGN
StockNews.AI
13 hrs

ORGANON ALERT: Bragar Eagel & Squire, P.C. is Investigating Organon & Co. on Behalf of Organon Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire is investigating Organon for potential securities law violations. 2. Organon reported a 7% revenue decline to $1.51B in Q1 FY25 results. 3. Dividends were cut from $0.28 to $0.02, over 92% decrease. 4. Organon's stock fell more than 28% after the negative earnings report. 5. The declines were largely due to Biosimilars and Established Brands performance.

4 mins saved
Full Article

FAQ

Why Very Bearish?

Organon's drastic revenue decline and dividend cut signal significant operational issues, impacting investor confidence. Historical parallels exist when stock prices dropped sharply following poor earnings and dividend reductions, as seen with other pharmaceutical companies.

How important is it?

The article discusses significant operational troubles at Organon, directly associated with stockholder rights and potential lawsuits which can heavily affect stock price. The financial performance and legal scrutiny are critical for investor sentiment.

Why Short Term?

Immediate investor reaction likely due to earnings report; legal investigations could prolong negativity. For instance, in similar situations, stocks often show continued weakness during investigations.

Related Companies

AMGNPFEMRK
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Organon & Co. (“Organon” or the “Company”) (NYSE:OGN) on behalf of Organon stockholders. Our investigation concerns whether Organon has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. The majority of the decline was attributed to a 17% y/y decline in Biosimilars and an 11% y/y drop in Established Brands on the loss of Atozet exclusivity. On the back of these results, OGN announced it was cutting its dividend from $0.28 to $0.02 (a decrease of more than 92%). Following this news, the price of Organon stock fell more than 28% on the same day. If you purchased or otherwise acquired Organon shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News